利用免疫疗法治疗弥漫性大b细胞淋巴瘤。

IF 17.5 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2025-07-23 DOI:10.1016/j.trecan.2025.06.013

Jennifer K Lue, Sean E Healton, Gilles A Salles

{"title":"利用免疫疗法治疗弥漫性大b细胞淋巴瘤。","authors":"Jennifer K Lue, Sean E Healton, Gilles A Salles","doi":"10.1016/j.trecan.2025.06.013","DOIUrl":null,"url":null,"abstract":"Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of aggressive lymphomas driven by distinct biological pathways. Although historically divided into two major subtypes on the basis of putative cell of origin, detailed genomic analyses have revealed additional classifications with prognostic implications. Additionally, the lymphoma microenvironment adds a layer of complexity distinct from genetic subclassifications and influences disease trajectory and response to therapies. Herein, we review the emerging roles of immune-based therapies to address this complex interplay between intrinsic genetic drivers and the surrounding tumor microenvironment in DLBCL.","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":17.5000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Leveraging immunologically based therapies to treat diffuse large B-cell lymphoma.\",\"authors\":\"Jennifer K Lue, Sean E Healton, Gilles A Salles\",\"doi\":\"10.1016/j.trecan.2025.06.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of aggressive lymphomas driven by distinct biological pathways. Although historically divided into two major subtypes on the basis of putative cell of origin, detailed genomic analyses have revealed additional classifications with prognostic implications. Additionally, the lymphoma microenvironment adds a layer of complexity distinct from genetic subclassifications and influences disease trajectory and response to therapies. Herein, we review the emerging roles of immune-based therapies to address this complex interplay between intrinsic genetic drivers and the surrounding tumor microenvironment in DLBCL.\",\"PeriodicalId\":23336,\"journal\":{\"name\":\"Trends in cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":17.5000,\"publicationDate\":\"2025-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.trecan.2025.06.013\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2025.06.013","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

弥漫性大b细胞淋巴瘤（DLBCL）是一种由不同生物学途径驱动的异质性侵袭性淋巴瘤。虽然历史上根据假定的细胞起源分为两种主要亚型，但详细的基因组分析揭示了具有预后意义的其他分类。此外，淋巴瘤微环境增加了一层不同于遗传亚分类的复杂性，并影响疾病轨迹和对治疗的反应。在此，我们回顾了基于免疫疗法的新兴作用，以解决DLBCL中内在遗传驱动因素与周围肿瘤微环境之间复杂的相互作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Leveraging immunologically based therapies to treat diffuse large B-cell lymphoma.

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of aggressive lymphomas driven by distinct biological pathways. Although historically divided into two major subtypes on the basis of putative cell of origin, detailed genomic analyses have revealed additional classifications with prognostic implications. Additionally, the lymphoma microenvironment adds a layer of complexity distinct from genetic subclassifications and influences disease trajectory and response to therapies. Herein, we review the emerging roles of immune-based therapies to address this complex interplay between intrinsic genetic drivers and the surrounding tumor microenvironment in DLBCL.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.